Arcturus Therapeutics Holdings Inc.
ARCTArcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA (siRNA), messenger RNA (mRNA), gene editing RNA, DNA, antisense oligonucleotides, and microRNA.
Drugs in Pipeline
5
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Jun 1, 2026
11wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
ARCT-2303
COVID-19
ARCT-810
OTC Deficiency
ARCT-032
Cystic Fibrosis
ARCT-165
COVID-19
ARCT-021 Dose 1
SARS-CoV-2
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ARCT-2303 | Phase 3 | COVID-19 | - | - |
ARCT-810 | Phase 2 | OTC Deficiency | - | - |
ARCT-032 | Phase 2 | Cystic Fibrosis | - | - |
ARCT-165 | Phase 2 | COVID-19 | - | - |
ARCT-021 Dose 1 | Phase 2 | SARS-CoV-2 | - | - |